A healthcare company that runs one of the world's largest clinical laboratory networks, performing blood tests and diagnostics for hospitals, doctors, and patients nationwide. Founded in 1967 as Metropolitan Pathology Laboratory by a resident doctor working in a two-bedroom Manhattan apartment — his lab famously started over a bathtub — it was renamed Quest Diagnostics in 1996 after glassmaker Corning spun it off. Its brands include the MyQuest patient app and ExamOne life-insurance exams.
Quest Diagnostics issues $500M of 5.000% senior notes due 2036
Interest on the notes will be paid semiannually on June 30 and December 30, beginning December 30, 2026.
Show detailsHide details
On May 6, 2026, Quest Diagnostics issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036.
The notes mature on June 30, 2036, and are senior unsecured obligations ranking equally with existing and future senior unsecured debt.
The notes were issued under an indenture supplemented by a twenty-fourth supplemental indenture dated May 6, 2026, with The Bank of New York Mellon as trustee.
Upon a change of control triggering event, the company must offer to repurchase the notes at 101% of principal plus accrued interest.
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
Quest Diagnostics elects Timothy Wentworth, former Walgreens Boots Alliance CEO, to its board
On March 9, 2026, the Board of Directors elected Timothy Wentworth as a director, effective immediately.
Show detailsHide details
Wentworth will serve on the Compensation and Leadership Development Committee and the Quality and Compliance Committee.
He is deemed an independent director under NYSE listing standards and the company's governance guidelines.
As a non-employee director, he received a prorated one-time grant of restricted share units valued at approximately $43,000.
With Wentworth's election, the board now has eleven members.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Quest Diagnostics reports Q4 and FY2025 results; raises dividend 7.5% and adds $1B buyback
Q4 2025 revenues were $2.81 billion, up 7.1% from Q4 2024.
Show detailsHide details
Full year 2025 revenues were $11.04 billion, up 11.8% from 2024.
Q4 2025 reported diluted EPS was $2.18, up 11.8%; adjusted diluted EPS was $2.42, up 8.5%.
Full year 2025 reported diluted EPS was $8.75, up 13.8%; adjusted diluted EPS was $9.85, up 10.3%.
Board authorized $1 billion additional share repurchases and increased quarterly dividend from $0.80 to $0.86 per share, effective with April 20, 2026 payment.
2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits
Quest Diagnostics presents at J.P. Morgan Healthcare Conference, reiterates long-term outlook
Quest Diagnostics presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, discussing strategy, performance, and market trends.
Show detailsHide details
The company reiterated its long-term outlook beyond 2025 of 4%-5% revenue CAGR and 7%-9% adjusted EPS CAGR.
Quest expects advanced diagnostic tests in five key clinical areas to generate ~$1 billion in 2025 revenue.
The company targets $4.5B-$5.0B operating cash flow and $3.0B-$3.3B free cash flow for 2025-2027.
M&A has deployed ~$2.8B in capital over the last three years, generating over $1B in annual revenue.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits